<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03722498</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-H171011</org_study_id>
    <nct_id>NCT03722498</nct_id>
  </id_info>
  <brief_title>Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE</brief_title>
  <official_title>Randomized Phase Ⅱ Study of Second-line Treatment Comparing Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-fluorouracil and Leucovorin With Sorafenib in Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangzhou No.12 People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaiping Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of combined hepatic arterial infusion chemotherapy (HAIC) of
      oxaliplatin, 5-fluorouracil and leucovorin and sorafenib in hepatocellular carcinoma (HCC)
      refractory to transarterial chemoembolization(TACE)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In most current guidelines, sorafenib is considered as the second-line treatment for patients
      with transarterial chemoembolization(TACE) failure or refractoriness.However,the median
      overall survival of those treated with sorafenib monotherapy was 16.4 to 24.7 months.

      Whether combining sorafenib with hepatic arterial infusion chemotherapy(HAIC) of
      oxaliplatin,5-fluorouracil and leucovorin is safe, well tolerated, and efficacious remains
      unknown, with no prospective clinical data currently available.The investigators therefore
      conducted a prospective and randomized phase II trial to compare the safety and efficacy of
      HAIC with sorafenib in patients refractory to TACE
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    protocol violation
  </why_stopped>
  <start_date type="Actual">June 1, 2016</start_date>
  <completion_date type="Actual">November 22, 2018</completion_date>
  <primary_completion_date type="Actual">November 22, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months</time_frame>
    <description>The period from the date of the start of HAIC or sorafenib until the date of the confirmation of tumor progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>12 months</time_frame>
    <description>The period from the date of the start of HAIC or sorafenib until the date of the confirmation of tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 Days after HAIC and TACE</time_frame>
    <description>Postoperative adverse events were graded based on CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Best response based on mRECIST</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HAIC of FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hepatic arterial infusion chemotherapy with oxaliplatin 85 mg/m2 on day 1, leucovorin 400 mg/m2 on days 1, and 5-fluorouracil 2800 mg/m2 on days 1 and 2, repeated every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib 400 mg orally twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HAIC of FOLFOX</intervention_name>
    <description>administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries</description>
    <arm_group_label>HAIC of FOLFOX</arm_group_label>
    <other_name>Oxaliplatin , fluorouracil, and leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>administration of Sorafenib</description>
    <arm_group_label>Sorafenib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  TACE failure or refractoriness based on the Liver Cancer Study Group of Japan (LCSGJ)
             criteria, including appearance of vascular invasion or two or more consecutive
             insufficient responses of the intrahepatic lesion;

          -  Except for TACE, patients have received no previous anti-tumor treatment;

          -  The diagnosis of HCC was based on histological results;

          -  Patients must have at least one tumor lesion that can be accurately measured;

          -  Not amendable to surgical resection ,local ablative therapy and any other cured
             treatment;

          -  No Cirrhosis or cirrhotic status of Child-Pugh class A only;

          -  No liver protection therapy in 2 weeks before enrolled, and meet the following
             laboratory parameters:(a) Platelet count ≥ 75,000/μL; (b)Hemoglobin ≥ 8.5 g/dL;(c)
             Total bilirubin ≤ 30mmol/L;(d) Serum albumin ≥ 32 g/L;(e) ASL and AST ≤ 5 x upper
             limit of normal;(f) Serum creatinine ≤ 1.5 x upper limit of normal;(g) INR &gt; 2.3 or
             PT/APTT within normal limits; (h) Absolute neutrophil count (ANC) &gt;1,500/mm3;

          -  Ability to understand the protocol and to agree to and sign a written informed consent
             document

        Exclusion Criteria:

          -  Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or
             hepatic encephalopathy;

          -  Known history of HIV;

          -  History of organ allograft;

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial;

          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy;

          -  Any other hemorrhage/bleeding event &gt; CTCAE Grade 3 within 4 weeks of first dose of
             study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Department of Hepatobiliary Oncology of Sun Yat-sen University Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangzhou Twelfth People 's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510620</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ming Shi</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiping Central Hospital</name>
      <address>
        <city>Kaiping</city>
        <state>Guangdong</state>
        <zip>529300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Proffesor</investigator_title>
  </responsible_party>
  <keyword>Hepatic arterial infusion chemotherapy</keyword>
  <keyword>Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

